Sanofi’s Multiple Sclerosis Drug Faces FDA Setback Over Safety and Efficacy Concerns
In a recent regulatory update, the FDA declined approval of Sanofi’s tolebrutinib for a specific form of multiple sclerosis, citing concerns relating to toxicities and ambiguous clinical efficacy. This decision presents a significant hurdle for the therapy's development.
FDA Decision
The FDA issued a complete response letter to Sanofi indicating that its MS drug tolebrutinib failed to meet standards due to safety concerns and insufficient demonstration of benefit.
Implications for MS Treatment
This outcome creates uncertainty around the availability of new therapeutic options for patients with specific forms of multiple sclerosis.
Next Steps
Sanofi will need to address the FDA’s concerns, potentially through additional trials or data submissions.
Source
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.